CHANG DAVID D (President and CEO) sold 1.8% of their position (95.27K shares) of ALLOGENE THERAPEUTICS, INC. on the open market

Open‑market sale worth $171.5K — a minor trim. Review remaining holdings and any 10b5‑1 plan disclosures.

S · 1 sale

CHANG DAVID D

Filed: 2/4/2026ACC: 0001737287-26-000009

InsiderCHANG DAVID DCIK 1611024

→

IssuerALLOGENE THERAPEUTICS, INC.CIK 1737287

DirectorOfficer· President and CEO

Since Oct 2018

+1.69M

Net shares

Net buyer

$171.5K

Total sold

Open market trades

0B · 1S

Total transactions

1.78M acquired · 95.27K disposed

Non-Derivative Transactions1

Common Stock

Direct

S · Sale

−95.27K

Price / share

$1.80

Trade value

$171.48K

% of position

1.8%

2/2/2026

5.28M→5.19M

Total

Net shares

−95.27K

Net value

-$171.48K

Security	Date	Type	Shares	Price / Share	Trade Value	% of Position	Held Before	Held After
Common Stock Direct	2/2/2026	S · Sale	−95.27K	$1.80	$171.48K	1.8%	5.28M	5.19M
Total			−95.27K		-$171.48K

Derivative Transactions2

Stock Option (Right to buy)

Direct

A · Award

Converts to

Common Stock

1.39M shares

+1.39M

Strike price

1.87

Held after

1.39M

Exercisable

—

2/2/2026

Restricted Stock Unit

Direct

A · Award

Converts to

Common Stock

392.59K shares

+392.59K

Strike price

Held after

392.59K

Exercisable

—

2/2/2026

Security	Converts To	Date	Type	Shares	Strike Price	Exercisable	Held After
Stock Option (Right to buy) Direct	Common Stock1.39M shares	2/2/2026	A · Award	+1.39M	1.87	—	1.39M
Restricted Stock Unit Direct	Common Stock392.59K shares	2/2/2026	A · Award	+392.59K		—	392.59K

Non-Derivative Holdings (Post-Transaction)3

Common Stock

Indirect

Shares owned856.04K

Common Stock

Indirect

Shares owned1.20M

Common Stock

Indirect

Shares owned856.04K

Total

2.91M indirect2.91M

Security Title	Shares Owned	Ownership Type
Common Stock	856.04K	Indirect
Common Stock	1.20M	Indirect
Common Stock	856.04K	Indirect
Total	2.91M	2.91M indirect

Derivative Holdings (Post-Transaction)0

No derivative holdings reported